Long-term outcome of male-limited gonadotropin-independent precocious puberty

Silvano Bertelloni, Giampiero I. Baroncelli, Roberto Lala, Marco Cappa, Patrizia Matarazzo, Carlo De Sanctis, Giuseppe Saggese

Research output: Contribution to journalArticle

Abstract

Long-term outcome of five new cases of male-limited precocious puberty (MPP) is reported. Three patients had positive family history. One patient was untreated; 2 boys received cyproterone acetate (2.0-3.6 mg/kg/daily) without clinical effects. Two patients were treated with ketoconazole (600 mg/daily); in 1, GnRH analogue therapy (Buserelin, 1,600 μg/day) was added after 6 months of effective ketoconazole treatment for development of central precocious puberty. The other patient did not develop central puberty under ketoconazole treatment and improved his predicted adult height from 172.4 to 181.1 cm. Four patients reached final height [B.A. (therapy cyproterone acetate): age 22.0 years, -2.0 SDS; B.G. (untreated): age 15.5 years, -1.7 SDS; M.M. (therapy cyproterone acetate): age 19.5 years, -1.6 SDS; M.F. (therapy ketoconazole plus GnRH analogue): age 21.3 years, -2.2 SDS]; three had reduced testicular volume (B.A.: -1.6/-1.6 SDS; B.G.: -2.1/-2.1 SDS; M.F.: -2.4/-1.9 SDS); one (M.F.) showed oligospermia. We concluded that in MPP cyproterone acetate treatment did not improve final height; ketoconazole was effective in reducing testosterone secretion, but its real effect on final height cannot be determined; the timing of central puberty may be precocious, suggesting that an adjunctive GnRH analogue treatment may be needed. In some patients, testicular impairment may be present in young adulthood.

Original languageEnglish
Pages (from-to)235-239
Number of pages5
JournalHormone Research
Volume48
Issue number5
Publication statusPublished - Nov 1997

Fingerprint

Ketoconazole
Cyproterone Acetate
Gonadotropin-Releasing Hormone
Therapeutics
Puberty
Buserelin
Oligospermia
Familial Testotoxicosis
Testosterone

Keywords

  • Cyproterone acetate
  • Final height
  • Growth
  • Ketoconazole
  • Male-limited precocious puberty
  • Testicular failure

ASJC Scopus subject areas

  • Endocrinology

Cite this

Bertelloni, S., Baroncelli, G. I., Lala, R., Cappa, M., Matarazzo, P., De Sanctis, C., & Saggese, G. (1997). Long-term outcome of male-limited gonadotropin-independent precocious puberty. Hormone Research, 48(5), 235-239.

Long-term outcome of male-limited gonadotropin-independent precocious puberty. / Bertelloni, Silvano; Baroncelli, Giampiero I.; Lala, Roberto; Cappa, Marco; Matarazzo, Patrizia; De Sanctis, Carlo; Saggese, Giuseppe.

In: Hormone Research, Vol. 48, No. 5, 11.1997, p. 235-239.

Research output: Contribution to journalArticle

Bertelloni, S, Baroncelli, GI, Lala, R, Cappa, M, Matarazzo, P, De Sanctis, C & Saggese, G 1997, 'Long-term outcome of male-limited gonadotropin-independent precocious puberty', Hormone Research, vol. 48, no. 5, pp. 235-239.
Bertelloni S, Baroncelli GI, Lala R, Cappa M, Matarazzo P, De Sanctis C et al. Long-term outcome of male-limited gonadotropin-independent precocious puberty. Hormone Research. 1997 Nov;48(5):235-239.
Bertelloni, Silvano ; Baroncelli, Giampiero I. ; Lala, Roberto ; Cappa, Marco ; Matarazzo, Patrizia ; De Sanctis, Carlo ; Saggese, Giuseppe. / Long-term outcome of male-limited gonadotropin-independent precocious puberty. In: Hormone Research. 1997 ; Vol. 48, No. 5. pp. 235-239.
@article{e1e5f568195143bb9dcf070476821bf2,
title = "Long-term outcome of male-limited gonadotropin-independent precocious puberty",
abstract = "Long-term outcome of five new cases of male-limited precocious puberty (MPP) is reported. Three patients had positive family history. One patient was untreated; 2 boys received cyproterone acetate (2.0-3.6 mg/kg/daily) without clinical effects. Two patients were treated with ketoconazole (600 mg/daily); in 1, GnRH analogue therapy (Buserelin, 1,600 μg/day) was added after 6 months of effective ketoconazole treatment for development of central precocious puberty. The other patient did not develop central puberty under ketoconazole treatment and improved his predicted adult height from 172.4 to 181.1 cm. Four patients reached final height [B.A. (therapy cyproterone acetate): age 22.0 years, -2.0 SDS; B.G. (untreated): age 15.5 years, -1.7 SDS; M.M. (therapy cyproterone acetate): age 19.5 years, -1.6 SDS; M.F. (therapy ketoconazole plus GnRH analogue): age 21.3 years, -2.2 SDS]; three had reduced testicular volume (B.A.: -1.6/-1.6 SDS; B.G.: -2.1/-2.1 SDS; M.F.: -2.4/-1.9 SDS); one (M.F.) showed oligospermia. We concluded that in MPP cyproterone acetate treatment did not improve final height; ketoconazole was effective in reducing testosterone secretion, but its real effect on final height cannot be determined; the timing of central puberty may be precocious, suggesting that an adjunctive GnRH analogue treatment may be needed. In some patients, testicular impairment may be present in young adulthood.",
keywords = "Cyproterone acetate, Final height, Growth, Ketoconazole, Male-limited precocious puberty, Testicular failure",
author = "Silvano Bertelloni and Baroncelli, {Giampiero I.} and Roberto Lala and Marco Cappa and Patrizia Matarazzo and {De Sanctis}, Carlo and Giuseppe Saggese",
year = "1997",
month = "11",
language = "English",
volume = "48",
pages = "235--239",
journal = "Hormone Research",
issn = "0301-0163",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Long-term outcome of male-limited gonadotropin-independent precocious puberty

AU - Bertelloni, Silvano

AU - Baroncelli, Giampiero I.

AU - Lala, Roberto

AU - Cappa, Marco

AU - Matarazzo, Patrizia

AU - De Sanctis, Carlo

AU - Saggese, Giuseppe

PY - 1997/11

Y1 - 1997/11

N2 - Long-term outcome of five new cases of male-limited precocious puberty (MPP) is reported. Three patients had positive family history. One patient was untreated; 2 boys received cyproterone acetate (2.0-3.6 mg/kg/daily) without clinical effects. Two patients were treated with ketoconazole (600 mg/daily); in 1, GnRH analogue therapy (Buserelin, 1,600 μg/day) was added after 6 months of effective ketoconazole treatment for development of central precocious puberty. The other patient did not develop central puberty under ketoconazole treatment and improved his predicted adult height from 172.4 to 181.1 cm. Four patients reached final height [B.A. (therapy cyproterone acetate): age 22.0 years, -2.0 SDS; B.G. (untreated): age 15.5 years, -1.7 SDS; M.M. (therapy cyproterone acetate): age 19.5 years, -1.6 SDS; M.F. (therapy ketoconazole plus GnRH analogue): age 21.3 years, -2.2 SDS]; three had reduced testicular volume (B.A.: -1.6/-1.6 SDS; B.G.: -2.1/-2.1 SDS; M.F.: -2.4/-1.9 SDS); one (M.F.) showed oligospermia. We concluded that in MPP cyproterone acetate treatment did not improve final height; ketoconazole was effective in reducing testosterone secretion, but its real effect on final height cannot be determined; the timing of central puberty may be precocious, suggesting that an adjunctive GnRH analogue treatment may be needed. In some patients, testicular impairment may be present in young adulthood.

AB - Long-term outcome of five new cases of male-limited precocious puberty (MPP) is reported. Three patients had positive family history. One patient was untreated; 2 boys received cyproterone acetate (2.0-3.6 mg/kg/daily) without clinical effects. Two patients were treated with ketoconazole (600 mg/daily); in 1, GnRH analogue therapy (Buserelin, 1,600 μg/day) was added after 6 months of effective ketoconazole treatment for development of central precocious puberty. The other patient did not develop central puberty under ketoconazole treatment and improved his predicted adult height from 172.4 to 181.1 cm. Four patients reached final height [B.A. (therapy cyproterone acetate): age 22.0 years, -2.0 SDS; B.G. (untreated): age 15.5 years, -1.7 SDS; M.M. (therapy cyproterone acetate): age 19.5 years, -1.6 SDS; M.F. (therapy ketoconazole plus GnRH analogue): age 21.3 years, -2.2 SDS]; three had reduced testicular volume (B.A.: -1.6/-1.6 SDS; B.G.: -2.1/-2.1 SDS; M.F.: -2.4/-1.9 SDS); one (M.F.) showed oligospermia. We concluded that in MPP cyproterone acetate treatment did not improve final height; ketoconazole was effective in reducing testosterone secretion, but its real effect on final height cannot be determined; the timing of central puberty may be precocious, suggesting that an adjunctive GnRH analogue treatment may be needed. In some patients, testicular impairment may be present in young adulthood.

KW - Cyproterone acetate

KW - Final height

KW - Growth

KW - Ketoconazole

KW - Male-limited precocious puberty

KW - Testicular failure

UR - http://www.scopus.com/inward/record.url?scp=0030733509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030733509&partnerID=8YFLogxK

M3 - Article

C2 - 9362394

AN - SCOPUS:0030733509

VL - 48

SP - 235

EP - 239

JO - Hormone Research

JF - Hormone Research

SN - 0301-0163

IS - 5

ER -